|
KMID : 0391119950040010036
|
|
Ulsan University Medical Journal
1995 Volume.4 No. 1 p.36 ~ p.43
|
|
|
CD23 and P-glycoprotein in De Novo Acute Myelogenous Leukemia
|
|
김성배
이규형/최종수/정대영/이재환/김상위/서철원/이정신/지현숙
|
|
|
Abstract
|
|
|
Backgrounds:
@EN The expression of the MDR-1(multidrug resistance)encoded P-170 glycoprotein(p-170) and CD34 have been well known to be associated with drug resistance in AML(acute myelogenous leukemia). P-170 and CD34 expression in AML have been reported as
unfavorable prognostic parameters separately.
@ES Methods:
@EN P-170 glycoprotein expression was analyzed in correlation with CD34 expression and clinical response in 15 consecutive patients with de novo acute myelgenous leukemia (AML). They were measured with flow cytometry after direct and indreot
immunofluorescence staining simultaneouly.
@ES Results:
@EN 1) The positive rate of P-glycoprotein and CD34 were in two of 15 patients(13%), seven of 15 patients(46%), respectively.
2) One of two P-170 positive patients as compared with 7 of 13 P-170 negative patients achieved a complete remission(CR), which showed no clinical significant difference.
3) There was no significant correlation bettween P-glycoprotein and CD34 expression(r=0.29, p=0.28).
4) In de novo acute myelogenous leukemia, there was no case which expressed both P-170 and CD34 simultaneously.
5) P-glycoprotein and CD34 were not expressed in acute promyelocytic leukemia group.
6) Cytogenetic abnormalities did no show any significant difference in the rate of P-glycoprotein expression, CD34 expression and complete remission.
@ES Conclusion:
@EN CD34 and P-glycoprotein in acute myelogenous leukemia were independent parameter in this study. Further investigations are warranted for clinical implication.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|